| 臺大學術典藏 |
2022-08-10T02:37:41Z |
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial
|
CHIH-HSIN YANG; Mok T.S.K.; Lu S.; Nakagawa K.; Yamamoto N.; Shi Y.-K.; Zhang L.; Soo R.A.; Morita S.; Tamura T. |
| 臺大學術典藏 |
2022-06-27T02:49:11Z |
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
|
Nadal E.; Horinouchi H.; JIN-YUAN SHIH; Nakagawa K.; Reck M.; Garon E.B.; Wei Y.-F.; Kollmeier J.; Frimodt-Moller B.; Barrett E.; Lipkovich O.; Visseren-Grul C.; Novello S. |
| 臺大學術典藏 |
2022-05-10T08:10:07Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU; Gralla R.J.; Gebski V.; Mok T.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-03-22T08:29:49Z |
Laminar HNb3O8-based membranes supported on anodic aluminum oxide with enhanced anti-swelling property for organic solvent nanofiltration
|
Nakagawa K;Kunimatsu M;Yasui K;Yoshioka T;Shintani T;Kamio E;Tung K.-L;Tsang S.C.E;Matsuyama H.; Nakagawa K; Kunimatsu M; Yasui K; Yoshioka T; Shintani T; Kamio E; Tung K.-L; Tsang S.C.E; Matsuyama H.; KUO-LUN TUNG |
| 臺大學術典藏 |
2022-03-22T08:29:49Z |
Controlling interlayer spacing and organic solvent permeation in laminar graphene oxide membranes modified with crosslinker
|
Nakagawa K;Araya S;Ushio K;Kunimatsu M;Yoshioka T;Shintani T;Kamio E;Tung K.-L;Matsuyama H.; Nakagawa K; Araya S; Ushio K; Kunimatsu M; Yoshioka T; Shintani T; Kamio E; Tung K.-L; Matsuyama H.; KUO-LUN TUNG |
| 臺大學術典藏 |
2022-03-22T08:29:48Z |
Controlling interlayer spacing and organic solvent permeation in laminar graphene oxide membranes modified with crosslinker
|
Nakagawa K;Araya S;Ushio K;Kunimatsu M;Yoshioka T;Shintani T;Kamio E;Tung K.-L;Matsuyama H.; Nakagawa K; Araya S; Ushio K; Kunimatsu M; Yoshioka T; Shintani T; Kamio E; Tung K.-L; Matsuyama H.; KUO-LUN TUNG |
| 臺大學術典藏 |
2022-03-22T08:29:48Z |
Laminar HNb3O8-based membranes supported on anodic aluminum oxide with enhanced anti-swelling property for organic solvent nanofiltration
|
Nakagawa K;Kunimatsu M;Yasui K;Yoshioka T;Shintani T;Kamio E;Tung K.-L;Tsang S.C.E;Matsuyama H.; Nakagawa K; Kunimatsu M; Yasui K; Yoshioka T; Shintani T; Kamio E; Tung K.-L; Tsang S.C.E; Matsuyama H.; KUO-LUN TUNG |
| 臺大學術典藏 |
2022-03-22T08:26:53Z |
Controlling interlayer spacing and organic solvent permeation in laminar graphene oxide membranes modified with crosslinker
|
Nakagawa K;Araya S;Ushio K;Kunimatsu M;Yoshioka T;Shintani T;Kamio E;Tung K.-L;Matsuyama H.; Nakagawa K; Araya S; Ushio K; Kunimatsu M; Yoshioka T; Shintani T; Kamio E; Tung K.-L; Matsuyama H.; KUO-LUN TUNG |
| 臺大學術典藏 |
2022-03-22T08:26:53Z |
Laminar HNb3O8-based membranes supported on anodic aluminum oxide with enhanced anti-swelling property for organic solvent nanofiltration
|
Nakagawa K;Kunimatsu M;Yasui K;Yoshioka T;Shintani T;Kamio E;Tung K.-L;Tsang S.C.E;Matsuyama H.; Nakagawa K; Kunimatsu M; Yasui K; Yoshioka T; Shintani T; Kamio E; Tung K.-L; Tsang S.C.E; Matsuyama H.; KUO-LUN TUNG |
| 臺大學術典藏 |
2021-11-03T02:32:59Z |
RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non?small cell lung cancer
|
Nakagawa K.; Nadal E.; Garon E.B.; Nishio M.; Seto T.; Yamamoto N.; Park K.; JIN-YUAN SHIH; Paz-Ares L.; Frimodt-Moller B.; Zimmermann A.H.; Wijayawardana S.; Visseren-Grul C.; Reck M. |
| 臺大學術典藏 |
2021-08-05T02:40:13Z |
A Numerical Simulation and Experimental Comparison of Atmospheric Thermal Plasma Spray Coatings between Internal and External Powder Injection Processes
|
Hsu T.-Y;Huang T.-C;Chou J.-H;Lin Y.-F;Nakagawa K;Yoshioka T;Matsuyama H;Tseng H.-H;Tung K.-L.; Hsu T.-Y; Huang T.-C; Chou J.-H; Lin Y.-F; Nakagawa K; Yoshioka T; Matsuyama H; Tseng H.-H; Tung K.-L.; KUO-LUN TUNG |
| 臺大學術典藏 |
2021-05-02T03:49:13Z |
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY
|
Nishio M.;Seto T.;Reck M.;Garon E.B.;Chiu C.-H.;Yoh K.;Imamura F.;Park K.;Jin-Yuan Shih;Visseren-Grul C.;Frimodt-Moller B.;Zimmermann A.;Homma G.;Enatsu S.;Nakagawa K.;Relay Study Investigators; Nishio M.; Seto T.; Reck M.; Garon E.B.; Chiu C.-H.; Yoh K.; Imamura F.; Park K.; JIN-YUAN SHIH; Visseren-Grul C.; Frimodt-Moller B.; Zimmermann A.; Homma G.; Enatsu S.; Nakagawa K.; RELAY Study Investigators |
| 臺大學術典藏 |
2021-04-23T05:56:33Z |
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
|
Chih-Hsin Yang;Cheng Y.;Murakami H.;Yang P.-C.;He J.;Nakagawa K.;Kang J.H.;Kim J.-H.;Hozak R.R.;Nguyen T.S.;Zhang W.L.;Enatsu S.;Puri T.;Orlando M.; CHIH-HSIN YANG; Cheng Y.; Murakami H.; Yang P.-C.; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M. |
| 臺大學術典藏 |
2020-12-02T02:33:19Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Wang X.; Enatsu S.; Puri T.; Orlando M.; Yang J.C.-H.; Cheng Y.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:06Z |
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
|
Yang J.C.-H.; PAN-CHYR YANG et al.; Yang J.C.-H.; Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M. |
| 臺大學術典藏 |
2020-05-26T09:27:11Z |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
|
Fukuoka M;Wu Y.-L;Thongprasert S;Sunpaweravong P;Leong S.-S;Sriuranpong V;Chao T.-Y;Nakagawa K;Chu D.-T;Saijo N;Duffield E.L;Rukazenkov Y;Speake G;Jiang H;Armour A.A;To K.-F;Chih-Hsin Yang;Mok T.S.K.; Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG; Mok T.S.K. |
| 臺大學術典藏 |
2020-05-26T09:26:58Z |
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III iressa pan-ASia study (IPASS)
|
Chih-Hsin Yang;Wu Y.-L;Chan V;Kurnianda J;Nakagawa K;Saijo N;Fukuoka M;Mcwalter G;Mccormack R;Mok T.S.K.; CHIH-HSIN YANG; Wu Y.-L; Chan V; Kurnianda J; Nakagawa K; Saijo N; Fukuoka M; McWalter G; McCormack R; Mok T.S.K. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial
|
CHIH-HSIN YANG; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Lee D.H; Liu Y; Yoh K; Zhou J.-Y; Shi X; Webster A; Jiang H; Mok T.S.K.; Mok T.S.K.;Jiang H;Webster A;Shi X;Zhou J.-Y;Yoh K;Liu Y;Lee D.H;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Chih-Hsin Yang;Kim S.-W;Nakagawa K;Wu Y.-L;Soria J.-C; Soria J.-C; Wu Y.-L; Nakagawa K; Kim S.-W |
| 臺大學術典藏 |
2020-05-26T09:26:55Z |
Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT
|
Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M. |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations
|
Chih-Hsin Yang;Orlando M;Puri T;Enatsu S;Wang X;Kim J.-H;Kang J.H;Nakagawa K;He J;Yang P.-C;Murakami H;Cheng Y; Cheng Y; Murakami H; Yang P.-C; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
|
Tamura T.;Morita S;Lim W.T;Cheng Y;Ichinose Y;Maemondo M;Chang J;Goto K;Takahashi T;Nishio M;Sugawara S;Chih-Hsin Yang;Soo R.A;Zhang L;Shi Y.K;Yamamoto N;Nakagawa K;Mok T.S.K;Lu S;Nokihara H; Nokihara H; Lu S; Mok T.S.K; Nakagawa K; Yamamoto N; Shi Y.K; Zhang L; Soo R.A; CHIH-HSIN YANG; Sugawara S; Nishio M; Takahashi T; Goto K; Chang J; Maemondo M; Ichinose Y; Cheng Y; Lim W.T; Morita S; Tamura T. |
| 臺大學術典藏 |
2020-05-26T09:26:41Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Chih-Hsin Yang;Mok T;Gebski V;Gralla R.J;Tu Y.-K;Marschner I;Lord S;Fukuoka M;Thongprasert S;Nakagawa K;Zhou C;Rosell R;Inoue A;Mitsudomi T;Wu Y.-L;Davies L;Lee C.K; Lee C.K; Davies L; Wu Y.-L; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu Y.-K; Gralla R.J; Gebski V; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
|
Syrigos K; van Meerbeeck J.P; van Zandwijk N; Chih-Hsin CHIH-HSIN YANG; Zhou C; Vokes E.; Vokes E.;Zhou C;Chih-Hsin Yang;Van Zandwijk N;Van Meerbeeck J.P;Syrigos K;Smit E.F;P?rol M;Papotti M;Novello S;Mornex F;Moniuszko M;Marabelle A;Huber R.M;Garrido P;Fennell D;Felip E;Crin? L;Brustugun O.T;Wu Y.-L;Reck M;Peters S;Nicolson M;Nakagawa K;Gray J.E;Dingemans A.-M.C;Manegold C; Manegold C; Dingemans A.-M.C; Gray J.E; Nakagawa K; Nicolson M; Peters S; Reck M; Wu Y.-L; Brustugun O.T; Crinò L; Felip E; Smit E.F; Pérol M; Papotti M; Fennell D; Garrido P; Huber R.M; Marabelle A; Moniuszko M; Mornex F; Novello S |
| 臺大學術典藏 |
2020-05-26T09:26:35Z |
Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in east asian patients with advanced nonsquamous non-small-cell lung cancer
|
Chih-Hsin Yang;Lin C.-B;Lee K.-H;Cho E.K;Park K;Tanaka H;Ichinose Y;Yamada K;Kato T;Kaneda H;Hayashi H;Nakagawa K;Yoh K;Hida T;Oshita F;Yoshioka H;Hara K;Asato T;Kubota K; Kubota K; Asato T; Hara K; Yoshioka H; Oshita F; Hida T; Yoh K; Nakagawa K; Hayashi H; Kaneda H; Kato T; Yamada K; Ichinose Y; Tanaka H; Park K; Cho E.K; Lee K.-H; Lin C.-B; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
